US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

METAGENOMI TECHNOLOGIES, LLC

us-stock
To Invest in {{usstockname}}
us-stock
$1.8 0.1383(13.83%) MGX at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 1.6
Highest Today 1.785
Today’s Open 1.6
Prev. Close 1.555
52 Week High 4.92
52 Week Low 1.23
Day’s Range: Low 1.6 High 1.785
52-Week Range: Low 1.23 High 4.92
1 day return -
1 Week return +2.31
1 month return -22.36
3 month return -0.28
6 month return +4.73
1 year return -5.85
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 4

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 58.39 M

PB Ratio 0.3682

PE Ratio 0.0

Enterprise Value -76.74 M

Total Assets 324.60 M

Volume 584747

Company Financials

Annual Revenue FY23:44756000 44.8M

Annual Profit FY23:null 0.0M

Annual Net worth FY23:-68255000 -68.3M

Quarterly Revenue Q3/2025:8659000 8.7M, Q2/2025:8513000 8.5M, Q1/2025:4127000 4.1M, Q3/2024:11514000 11.5M, Q2/2024:20008000 20.0M

Quarterly Profit Q3/2025:7335000 7.3M, Q2/2025:-13994000 -14.0M, Q1/2025:4127000 4.1M, Q3/2024:11514000 11.5M, Q2/2024:18699000 18.7M

Quarterly Net worth Q3/2025:-20393000 -20.4M, Q2/2025:-19908000 -19.9M, Q1/2025:-25039000 -25.0M, Q3/2024:-18773000 -18.8M, Q2/2024:-10739000 -10.7M

Fund house & investment objective

Company Information Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Organisation Biotechnology

Employees 124

Industry Biotechnology

CEO Dr. Jian Irish M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right